CMP as on 06-Jul-22 15:29₹ 296.50
Turnover (lac)₹ 95
Prev. Close₹ 300.10
Day's Vol (shares)₹ 32,044
Day's Range (₹)
CMP as on06-Jul-22 15:54₹ 297.45
Turnover (lac)₹ 61
Prev. Close₹ 299.15
Day's Vol (shares)₹ 29,811
Company looks to enter the Australian markets soon with its dermatology, gastro and pain management products and gradually expand produ
Company is planning to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic a
The company posted an almost 120% jump in first-quarter profit to $466 million and revenue rose 27% to $16.9 billion from $13.3 billion
Company recommends dividend of 15% - Rs1.5 per share for FY 21.
The company reported an EBITDA of Rs16.74cr in Q4FY21, a rise of 28.25% as compared to Rs13.05cr in the corresponding period last year.
Rating agency ICRA has recently upgraded the company's long-term and short-term bank facilities to A and A1 respectively.
Short term bank facilities has been upgraded from ICRA A2+ to ICRA A1.
The healthcare companys net revenue for the Q3FY21 was reported at Rs113.26cr, higher by 15.56% over net revenue of Rs98.01cr in Q3FY20
Lincoln Pharma stocks were trading at Rs222.75 apiece on the BSE at around 1:35 PM down by 5.31% or Rs12.50.
Export business of the company has shown remarkable growth in the last few years. Exports have increased to 56% of total sales in FY20
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity